Global pharmaceutical giant Roche has agreed to buy San Diego based Seragon for up to $1.7 billion. More than half of that amount is dependent on meeting development targets. The purchase of the company, which is only a year old, is largely due to its innovative work on breast cancer treatment; a drug that can block estrogen , a major factor in the spread of tumors. Although the drug is at an early stage of testing, a Roche statement acknowledges that it “could one day redefine the standard of care for hormone receptor-positive breast cancer.” Read the full story.
More market talk: